CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Safety and efficacy in lamivudine experienced chronic hepatitis B (CHB) patients treated for two years with tenofovir disoproxil fumarate
DOI 10.1055/s-0029-1241526
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Manns, P Buggisch, S Mauss, T Berg, G Teuber, M Schuchmann, P Marcellin, J Heathcote, J Sorbel, F Rousseau
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe09/2009
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: Tenofovir disoproxil fumarate (TDF) is active against lamivudine resistant hepatitis B virus (HBV). Response to TDF treatment in a subset of patients from the phase 3, studies 102 (HBeAg-negative patients) and 103 (HBeAg-positive patients) previously treated for >12 weeks with lamivudine or emtricitabine (LAM-experienced) was compared to LAM-naïve patients in these two studies. Goal: To determine if th…
Zitieren
Zitierempfehlung
M Manns, P Buggisch, S Mauss, T Berg, G Teuber, M Schuchmann, P Marcellin, J Heathcote, J Sorbel, F Rousseau (2009) Safety and efficacy in lamivudine experienced chronic hepatitis B (CHB) patients treated for two years with tenofovir disoproxil fumarate. Zeitschrift für Gastroenterologie (09). https://doi.org/10.1055/s-0029-1241526
Mit CareLit weiterarbeiten